+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Nosocomial multi-drug resistant Acinetobacter baumannii bloodstream infection: risk factors and outcome with ampicillin-sulbactam treatment



Nosocomial multi-drug resistant Acinetobacter baumannii bloodstream infection: risk factors and outcome with ampicillin-sulbactam treatment



Journal of Hospital Infection 54(1): 32-38



The emergence of multidrug-resistant (MDR) Acinetobacter baumannii poses a therapeutic problem. The aim of this study was to assess the risk factors for nosocomial MDR-A. baumannii bloodstream infection (BSI) and the efficacy of ampicillin-sulbactam (A/S) in its treatment. Of 94 nosocomial A. baumannii BSI during the year 2000, 54% involved MDR strains, 81% of which were genetically related. Various risk factors for MDR-A. baumannii were found, of which intensive-care unit admission and prior aminoglycoside therapy were independently associated with MDR-A. baumannii acquisition on multivariate analysis. Of MDR-A. baumannii BSI cases, 65% received A/S and 35% inadequate antibiotic therapy, whereas of 43 non-MDR cases, 86% were treated according to susceptibility and 14% inappropriately with antibiotics to which these organisms were resistant. Crude mortality was comparable in the adequately treated groups. Respective mortalities among patients treated adequately and inadequately were 41.4 and 91.7% (p<0.001). Among severely ill patients, A/S therapy significantly decreased the risk of death (P=0.02 OR=7.64). MDR-A. baumannii has become highly endemic in our institution. A/S appears to be one of the last effective and safe empirical resorts for treatment of MDR A. baumannii BSI.

(PDF emailed within 0-6 h: $19.90)

Accession: 035405660

Download citation: RISBibTeXText

PMID: 12767844

DOI: 10.1016/s0195-6701(03)00046-x


Related references

Risk factors for bloodstream infection with multi-drug resistant Acinetobacter baumannii. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 42: 301, 2002

Risk factors for multi-drug resistant Acinetobacter baumannii nosocomial infection. Journal of the Medical Association of Thailand 90(8): 1633-1639, 2007

Incidence, risk factors and outcome of multi-drug resistant Acinetobacter baumannii nosocomial infections during an outbreak in a burn unit. International Journal of Infectious Diseases 2018, 2018

Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin/sulbactam. International Journal of Antimicrobial Agents 21(1): 58-62, 2003

Successful treatment of extensively drug-resistant Acinetobacter baumannii peritoneal dialysis peritonitis with intraperitoneal polymyxin B and ampicillin-sulbactam. Annals of PharmacoTherapy 46(7-8): E17, 2012

A multi-center study on the risk factors of infection caused by multi-drug resistant Acinetobacter baumannii. Bmc Infectious Diseases 18(1): 11, 2018

Epidemiology of bloodstream infections caused by Acinetobacter baumannii and impact of drug resistance to both carbapenems and ampicillin-sulbactam on clinical outcomes. Antimicrobial Agents and ChemoTherapy 57(12): 6270-6275, 2014

Successful treatment of skin and soft tissue infection due to carbapenem-resistant Acinetobacter baumannii by ampicillin-sulbactam and meropenem combination therapy. International Journal of Infectious Diseases 17(12): E1234-6, 2014

Risk factors associated with multi-drug-resistant Acinetobacter baumannii nosocomial infections at a tertiary care hospital in Makkah, Saudi Arabia - a matched case-control study. Journal of International Medical Research 45(3): 1181-1189, 2017

Retrospective comparative analysis of risk factors and outcomes in patients with carbapenem-resistant Acinetobacter baumannii bloodstream infections: cefoperazone-sulbactam associated with resistance and tigecycline increased the mortality. Infection and Drug Resistance 11: 2021-2030, 2018

Treatment of multidrug-resistant Acinetobacter baumannii meningitis with ampicillin/sulbactam. Clinical Infectious Diseases 24(5): 932-935, 1997

Comparison of Tigecycline or Cefoperazone/Sulbactam therapy for bloodstream infection due to Carbapenem-resistant Acinetobacter baumannii. Antimicrobial Resistance and Infection Control 8: 52, 2019

In vitro activities of ampicillin, sulbactam and a combination of ampicillin and sulbactam against isolates of Acinetobacter calcoaceticus-Acinetobacter baumannii complex isolated in Chile between 1990 and 1998. Journal of Antimicrobial ChemoTherapy 45(5): 712-713, 2000

Nosocomial outbreak of multi-resistant Acinetobacter baumannii on a surgical ward: epidemiology and risk factors for acquisition. Journal of Hospital Infection 37(2): 113-123, 1997

Attributable mortality of imipenem-resistant nosocomial Acinetobacter baumannii bloodstream infection. Journal of the Medical Association of Thailand 92(3): 413-419, 2009